Metabolic, anabolic, and mitogenic insulin responses: A tissue-specific perspective for insulin receptor activators

Molecular and Cellular Endocrinology

Volumn 415, Issue , 2015, Pages 143-156

  Bedinger, Daniel H ^a   Adams, Sean H ^b  

^a XOMA Corporation   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Akt; Diabetes; ERK; Insulin; Insulin receptor; Insulin like growth factor

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR AGONIST; PROTEIN KINASE B; SOMATOMEDIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CANCER RISK; ENDOTHELIUM CELL; ENZYME ACTIVATION; GROWTH REGULATION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; LIVER; METABOLIC DISORDER; METABOLIC REGULATION; MICROANGIOPATHY; MITOGENESIS; MOLECULAR WEIGHT; MUSCLE; NEOPLASM; NERVE CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; VASCULAR ENDOTHELIUM; VASODILATATION; AGONISTS; ANTIBODY SPECIFICITY; METABOLIC DISEASES; METABOLISM;

HUMANS; INSULIN; MAP KINASE SIGNALING SYSTEM; METABOLIC DISEASES; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN;

EID: 84942609928     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.08.013     Document Type: Review

References (274)

1. Adams G.R. Invited review: autocrine/paracrine IGF-I and skeletal muscle adaptation. J. Appl. Physiol. (1985) 2002, 93:1159-1167.
2. Adams G.R., McCue S.A. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J. Appl. Physiol. (1985) 1998, 84:1716-1722.
3. Ahren B., Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 2001, 50:1030-1038.
4. Aly H., Rohatgi N., Marshall C.A., Grossenheider T.C., Miyoshi H., Stappenbeck T.S., Matkovich S.J., McDaniel M.L. A novel strategy to increase the proliferative potential of adult human beta-cells while maintaining their differentiated phenotype. PLoS One 2013, 8:e66131.
5. Andreozzi F., Laratta E., Sciacqua A., Perticone F., Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ. Res. 2004, 94:1211-1218.
6. Anisimov V.N., Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit. Rev. Oncol. Hematol. 2013, 87:201-223.
7. Arner P., Langin D. The role of neutral lipases in human adipose tissue lipolysis. Curr. Opin. Lipidol. 2007, 18:246-250.
8. Asrih M., Pellieux C., Papageorgiou I., Lerch R., Montessuit C. Role of ERK1/2 activation in microtubule stabilization and glucose transport in cardiomyocytes. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E836-E843.
9. Assmann A., Hinault C., Kulkarni R.N. Growth factor control of pancreatic islet regeneration and function. Pediatr. Diabetes 2009, 10:14-32.
10. Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 1997, 327(Pt 1):209-215.
11. Banks A.S., McAllister F.E., Camporez J.P., Zushin P.J., Jurczak M.J., Laznik-Bogoslavski D., Shulman G.I., Gygi S.P., Spiegelman B.M. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature 2014, 517(7534):391-395. 2015 Jan 15.
12. Bard-Chapeau E.A., Hevener A.L., Long S., Zhang E.E., Olefsky J.M., Feng G.S. Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat. Med. 2005, 11:567-571.
13. Baxter R.C. IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer 2014, 14:329-341.
14. Bedinger D.H., Kieffer D.A., Goldfine I.D., Roell M.K., Adams S.H. Acute treatment with XMetA activates hepatic insulin receptors and lowers blood glucose in normal mice. J. Cell Biochem. 2015, 116(9):2109-2119. 2015 Sep.
15. Bedinger D.H., Goldfine I.D., Corbin J.A., Roell M.K., Adams S.H. Differential Pathway Coupling of the Activated Insulin Receptor Drives Signaling Selectivity by XMetA, an Allosteric Partial Agonist Antibody. J. Pharmacol. Exp. Ther. 2015, 353(1):35-43. 2015 Apr.
16. Belardi V., Gallagher E.J., Novosyadlyy R., LeRoith D. Insulin and IGFs in obesity-related breast cancer. J. Mammary Gland. Biol. Neoplasia 2013, 18:277-289.
17. Belfiore A., Malaguarnera R. Insulin receptor and cancer. Endocr. Relat. Cancer 2011, 18:R125-R147.
18. Berlato C., Doppler W. Selective response to insulin versus insulin-like growth factor-I and -II and up-regulation of insulin receptor splice variant B in the differentiated mouse mammary epithelium. Endocrinology 2009, 150:2924-2933.
19. Bernal-Mizrachi E., Kulkarni R.N., Scott D.K., Mauvais-Jarvis F., Stewart A.F., Garcia-Ocana A. Human beta-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes 2014, 63:819-831.
20. Bhaskar V., Goldfine I.D., Bedinger D.H., Lau A., Kuan H.F., Gross L.M., Handa M., Maddux B.A., Watson S.R., Zhu S., Narasimha A.J., Levy R., Webster L., Wijesuriya S.D., Liu N., Wu X., Chemla-Vogel D., Tran C., Lee S.R., Wong S., Wilcock D., White M.L., Corbin J.A. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 2012, 61:1263-1271.
21. Biddinger S.B., Kahn C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 2006, 68:123-158.
22. Bluher M., Michael M.D., Peroni O.D., Ueki K., Carter N., Kahn B.B., Kahn C.R. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell. 2002, 3:25-38.
23. Bluher M., Kahn B.B., Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003, 299:572-574.
24. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3:1014-1019.
25. Bost F., Aouadi M., Caron L., Even P., Belmonte N., Prot M., Dani C., Hofman P., Pages G., Pouyssegur J., Le Marchand-Brustel Y., Binetruy B. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005, 54:402-411.
26. Brown P.M., Tompkins C.V., Juul S., Sonksen P.H. Mechanism of action of insulin in diabetic patients: a dose-related effect on glucose production and utilisation. Br. Med. J. 1978, 1:1239-1242.
27. Bruning J.C., Michael M.D., Winnay J.N., Hayashi T., Horsch D., Accili D., Goodyear L.J., Kahn C.R. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell. 1998, 2:559-569.
28. Bruning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., Klein R., Krone W., Muller-Wieland D., Kahn C.R. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289:2122-2125.
29. Bryant N.J., Govers R., James D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 2002, 3:267-277.
30. Cantley J., Choudhury A.I., Asare-Anane H., Selman C., Lingard S., Heffron H., Herrera P., Persaud S.J., Withers D.J. Pancreatic deletion of insulin receptor substrate 2 reduces beta and alpha cell mass and impairs glucose homeostasis in mice. Diabetologia 2007, 50:1248-1256.
31. Cariou B., Postic C., Boudou P., Burcelin R., Kahn C.R., Girard J., Burnol A.F., Mauvais-Jarvis F. Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology 2004, 145:1926-1932.
32. Caro J.F., Poulos J., Ittoop O., Pories W.J., Flickinger E.G., Sinha M.K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest. 1988, 81:976-981.
33. cdc.gov National Diabetes Statistics Report 2014, the U.S 2014, Center for Disease Control. http://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf.
34. Ceresa B.P., Pessin J.E. Insulin regulation of the Ras activation/inactivation cycle. Mol. Cell Biochem. 1998, 182:23-29.
35. Cersosimo E., DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 2006, 22:423-436.
36. Cersosimo E., Garlick P., Ferretti J. Regulation of splanchnic and renal substrate supply by insulin in humans. Metabolism 2000, 49:676-683.
37. Chakrabarti P., Kim J.Y., Singh M., Shin Y.K., Kim J., Kumbrink J., Wu Y., Lee M.J., Kirsch K.H., Fried S.K., Kandror K.V. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol. Cell Biol. 2013, 33:3659-3666.
38. Chandra R., Liddle R.A. Recent advances in the regulation of pancreatic secretion. Curr. Opin. Gastroenterol. 2014, 30:490-494.
39. Chap Z., Ishida T., Chou J., Hartley C.J., Entman M.L., Brandenburg D., Jones R.H., Field J.B. First-pass hepatic extraction and metabolic effects of insulin and insulin analogues. Am. J. Physiol. 1987, 252:E209-E217.
40. Cheng Z., Tseng Y., White M.F. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 2010, 21:589-598.
41. Cheng K.K., Lam K.S., Wu D., Wang Y., Sweeney G., Hoo R.L., Zhang J., Xu A. APPL1 potentiates insulin secretion in pancreatic beta cells by enhancing protein kinase Akt-dependent expression of SNARE proteins in mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8919-8924.
42. Cherrington A.D., Edgerton D., Sindelar D.K. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 1998, 41:987-996.
43. Chiasson J.L., Atkinson R.L., Cherrington A.D., Keller U., Sinclair-Smith B.C., Lacy W.W., Liljenquist J.E. Effects of insulin at two dose levels on gluconeogenesis from alanine in fasting man. Metabolism 1980, 29:810-818.
44. Chirieac D.V., Chirieac L.R., Corsetti J.P., Cianci J., Sparks C.E., Sparks J.D. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E1003-E1011.
45. Choi Y.S., Cho H.Y., Hoyt K.R., Naegele J.R., Obrietan K. IGF-1 receptor-mediated ERK/MAPK signaling couples status epilepticus to progenitor cell proliferation in the subgranular layer of the dentate gyrus. Glia 2008, 56:791-800.
46. Choi D., Cai E.P., Woo M. The redundant role of JAK2 in regulating pancreatic beta-cell mass. Islets 2011, 3:389-392.
47. Clemmons D.R. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J. Clin. Invest. 2004, 113:25-27.
48. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 2007, 6:821-833.
49. Colao A., Spiezia S., Di Somma C., Pivonello R., Marzullo P., Rota F., Musella T., Auriemma R.S., De Martino M.C., Lombardi G. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J. Endocrinol. Invest. 2005, 28:440-448.
50. Copps K.D., White M.F. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012, 55(10):2565-2582. 2012 Oct.
51. Corkey B.E. Banting lecture 2011: hyperinsulinemia: cause or consequence?. Diabetes 2012, 61:4-13.
52. Corp E.S., Woods S.C., Porte D., Dorsa D.M., Figlewicz D.P., Baskin D.G. Localization of 125I-insulin binding sites in the rat hypothalamus by quantitative autoradiography. Neurosci. Lett. 1986, 70:17-22.
53. Cozar-Castellano I., Fiaschi-Taesch N., Bigatel T.A., Takane K.K., Garcia-Ocana A., Vasavada R., Stewart A.F. Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr. Rev. 2006, 27:356-370.
54. Criswell D.S., Booth F.W., DeMayo F., Schwartz R.J., Gordon S.E., Fiorotto M.L. Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. Am. J. Physiol. 1998, 275:E373-E379.
55. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., DeFronzo R.A., Kahn C.R., Mandarino L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest. 2000, 105:311-320.
56. De Meyts P. The insulin receptor: a prototype for dimeric, allosteric membrane receptors?. Trends Biochem. Sci. 2008, 33:376-384.
57. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. North Am. 2004, 88:787-835. ix.
58. Defronzo R.A. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
59. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53:1270-1287.
60. DeFronzo R.A., Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32(Suppl. 2):S157-S163.
61. Del Prato S., Leonetti F., Simonson D.C., Sheehan P., Matsuda M., DeFronzo R.A. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994, 37:1025-1035.
62. Denley A., Bonython E.R., Booker G.W., Cosgrove L.J., Forbes B.E., Ward C.W., Wallace J.C. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol. Endocrinol. 2004, 18:2502-2512.
63. Desbois-Mouthon C., Wendum D., Cadoret A., Rey C., Leneuve P., Blaise A., Housset C., Tronche F., Le Bouc Y., Holzenberger M. Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J. 2006, 20:773-775.
64. Diggs-Andrews K.A., Zhang X., Song Z., Daphna-Iken D., Routh V.H., Fisher S.J. Brain insulin action regulates hypothalamic glucose sensing and the counterregulatory response to hypoglycemia. Diabetes 2010, 59:2271-2280.
65. Djiogue S., Nwabo Kamdje A.H., Vecchio L., Kipanyula M.J., Farahna M., Aldebasi Y., Seke Etet P.F. Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer 2013, 20:R1-R17.
66. Dobbins R.L., Chester M.W., Stevenson B.E., Daniels M.B., Stein D.T., McGarry J.D. A fatty acid- dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. J. Clin. Invest. 1998, 101:2370-2376.
67. Dong X.C., Copps K.D., Guo S., Li Y., Kollipara R., DePinho R.A., White M.F. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008, 8:65-76.
68. Dor Y., Brown J., Martinez O.I., Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429:41-46.
69. Duan L., Cobb M.H. Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:22314-22319.
70. Duarte A.I., Moreira P.I., Oliveira C.R. Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012, 2012:384017.
71. Dufresne S.D., Bjorbaek C., El-Haschimi K., Zhao Y., Aschenbach W.G., Moller D.E., Goodyear L.J. Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice. Mol. Cell Biol. 2001, 21:81-87.
72. Dunn T.N., Adams S.H. Relations between metabolic homeostasis, diet, and peripheral afferent neuron biology. Adv. Nutr. 2014, 5:386-393.
73. Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.H., Masiarz F., Kan Y.W., Goldfine I.D., et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985, 40:747-758.
74. Entingh-Pearsall A., Kahn C.R. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J. Biol. Chem. 2004, 279:38016-38024.
75. Erarslan E., Coskun Y., Turkay C., Koktener A., Aydogan T. IGF-I levels and visceral fat accumulation in colonic neoplasia. Clin. Res. Hepatol. Gastroenterol. 2014, 38:99-105.
76. Eringa E.C., Stehouwer C.D., van Nieuw Amerongen G.P., Ouwehand L., Westerhof N., Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2043-H2048.
77. Espelund U., Cold S., Frystyk J., Orskov H., Flyvbjerg A. Elevated free IGF2 levels in localized, early-stage breast cancer in women. Eur. J. Endocrinol. 2008, 159:595-601.
78. Fernandez A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., Filmore J., Shulman G.I., Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 2001, 15:1926-1934.
79. Fisslthaler B., Benzing T., Busse R., Fleming I. Insulin enhances the expression of the endothelial nitric oxide synthase in native endothelial cells: a dual role for Akt and AP-1. Nitric Oxide 2003, 8:253-261.
80. Flores-Riveros J.R., McLenithan J.C., Ezaki O., Lane M.D. Insulin down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:512-516.
81. Fluckey J.D., Vary T.C., Jefferson L.S., Farrell P.A. Augmented insulin action on rates of protein synthesis after resistance exercise in rats. Am. J. Physiol. 1996, 270:E313-E319.
82. Fluckey J.D., Knox M., Smith L., Dupont-Versteegden E.E., Gaddy D., Tesch P.A., Peterson C.A. Insulin-facilitated increase of muscle protein synthesis after resistance exercise involves a MAP kinase pathway. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1205-E1211.
83. Folli F., Okada T., Perego C., Gunton J., Liew C.W., Akiyama M., D'Amico A., La Rosa S., Placidi C., Lupi R., Marchetti P., Sesti G., Hellerstein M., Perego L., Kulkarni R.N. Altered insulin receptor signalling and beta-cell cycle dynamics in type 2 diabetes mellitus. PLoS One 2011, 6:e28050.
84. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., Goldfine I.D., Belfiore A., Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol. 1999, 19:3278-3288.
85. Frasca F., Pandini G., Vigneri R., Goldfine I.D. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 2003, 17:73-89.
86. Frasca F., Pandini G., Malaguarnera R., Mandarino A., Messina R.L., Sciacca L., Belfiore A., Vigneri R. Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J. Biol. Chem. 2007, 282:26077-26088.
87. Frebel K., Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 2006, 34:1287-1290.
88. Friedrichsen B.N., Neubauer N., Lee Y.C., Gram V.K., Blume N., Petersen J.S., Nielsen J.H., Moldrup A. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J. Endocrinol. 2006, 188:481-492.
89. Frojdo S., Vidal H., Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim. Biophys. Acta 2009, 1792:83-92.
90. Gabbay R.A., Sutherland C., Gnudi L., Kahn B.B., O'Brien R.M., Granner D.K., Flier J.S. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 1996, 271:1890-1897.
91. Galic S., Hauser C., Kahn B.B., Haj F.G., Neel B.G., Tonks N.K., Tiganis T. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol. Cell Biol. 2005, 25:819-829.
92. Gao S., Wassler M., Zhang L., Li Y., Wang J., Zhang Y., Shelat H., Williams J., Geng Y.J. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis 2014, 232:171-179.
93. Garcia-Ocana A., Takane K.K., Syed M.A., Philbrick W.M., Vasavada R.C., Stewart A.F. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. 2000, 275:1226-1232.
94. Garg S.K., Hirsch I.B., Skyler J.S. Insulin glargine and cancer-an unsubstantiated allegation. Diabetes Technol. Ther. 2009, 11:473-476.
95. Garvey W.T., Olefsky J.M., Marshall S. Insulin receptor down-regulation is linked to an insulin-induced postreceptor defect in the glucose transport system in rat adipocytes. J. Clin. Invest. 1985, 76:22-30.
96. Garvey W.T., Olefsky J.M., Marshall S. Insulin induces progressive insulin resistance in cultured rat adipocytes. Sequential effects at receptor and multiple postreceptor sites. Diabetes 1986, 35:258-267.
97. Gavin J.R., Roth J., Neville D.M., de Meyts P., Buell D.N. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc. Natl. Acad. Sci. U. S. A. 1974, 71:84-88.
98. Genua M., Pandini G., Cassarino M.F., Messina R.L., Frasca F. c-Abl and insulin receptor signalling. Vitam. Horm. 2009, 80:77-105.
99. Gibson T.B., Lawrence M.C., Gibson C.J., Vanderbilt C.A., McGlynn K., Arnette D., Chen W., Collins J., Naziruddin B., Levy M.F., Ehrlich B.E., Cobb M.H. Inhibition of glucose-stimulated activation of extracellular signal-regulated protein kinases 1 and 2 by epinephrine in pancreatic beta-cells. Diabetes 2006, 55:1066-1073.
100. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
101. Gogg S., Smith U., Jansson P.A. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes 2009, 58:2238-2245.
102. Goldfine A.B., Kulkarni R.N. Modulation of beta-cell function: a translational journey from the bench to the bedside. Diabetes Obes. Metab. 2012, 14(Suppl. 3):152-160.
103. Goldstein B.J., Dudley A.L. The rat insulin receptor: primary structure and conservation of tissue-specific alternative messenger RNA splicing. Mol. Endocrinol. 1990, 4:235-244.
104. Gong Y., Dou L.J., Liang J. Link between obesity and cancer: role of triglyceride/free fatty acid cycling. Eur. Rev. Med. Pharmacol. Sci. 2014, 18:2808-2820.
105. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., Hartwick W., Hoffman B., Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 2002, 20:42-51.
106. Goodyear L.J., Chang P.Y., Sherwood D.J., Dufresne S.D., Moller D.E. Effects of exercise and insulin on mitogen-activated protein kinase signaling pathways in rat skeletal muscle. Am. J. Physiol. 1996, 271:E403-E408.
107. Griffen S.C., Russell S.M., Katz L.S., Nicoll C.S. Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7300-7304.
108. Grimaldi-Bensouda L., Cameron D., Marty M., Barnett A.H., Penault-Llorca F., Pollak M., Charbonnel B., Riddle M., Mignot L., Boivin J.F., Khachatryan A., Rossignol M., Benichou J., Alperovitch A., Abenhaim L. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care 2014, 37:134-143.
109. Groop P.H., Forsblom C., Thomas M.C. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1:100-110.
110. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
111. Habener J.F., Stanojevic V. alpha-cell role in beta-cell generation and regeneration. Islets 2012, 4:188-198.
112. Haddad F., Adams G.R. Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. J. Appl. Physiol. (1985) 2004, 96:203-210.
113. Hansen B.F., Danielsen G.M., Drejer K., Sorensen A.R., Wiberg F.C., Klein H.H., Lundemose A.G. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. 1996, 315(Pt 1):271-279.
114. Hansen B.F., Kurtzhals P., Jensen A.B., Dejgaard A., Russell-Jones D. Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 2011, 54:2226-2231.
115. Harbrecht B.G., Nweze I., Smith J.W., Zhang B. Insulin inhibits hepatocyte iNOS expression induced by cytokines by an Akt-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G116-G122.
116. Hauner H., Stockamp B., Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp. Clin. Endocrinol. Diabetes 1996, 104:106-110.
117. Hayashi T., Hirshman M.F., Kurth E.J., Winder W.W., Goodyear L.J. Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998, 47:1369-1373.
118. Huang C., Thirone A.C., Huang X., Klip A. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J. Biol. Chem. 2005, 280:19426-19435.
119. Ish-Shalom D., Christoffersen C.T., Vorwerk P., Sacerdoti-Sierra N., Shymko R.M., Naor D., De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997, 40(Suppl. 2):S25-S31.
120. Jager J., Corcelle V., Gremeaux T., Laurent K., Waget A., Pages G., Binetruy B., Le Marchand-Brustel Y., Burcelin R., Bost F., Tanti J.F. Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity. Diabetologia 2011, 54:180-189.
121. Janssen J.A., Varewijck A.J. Insulin analogs and cancer: a note of caution. Front. Endocrinol. (Lausanne) 2014, 5:79.
122. Jensen M., Hansen B., De Meyts P., Schaffer L., Urso B. Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J. Biol. Chem. 2007, 282:35179-35186.
123. Jiao P., Feng B., Li Y., He Q., Xu H. Hepatic ERK activity plays a role in energy metabolism. Mol. Cell Endocrinol. 2013, 375:157-166.
124. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
125. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
126. Kamagate A., Dong H.H. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 2008, 7:3162-3170.
127. Kappeler L., De Magalhaes Filho C., Dupont J., Leneuve P., Cervera P., Perin L., Loudes C., Blaise A., Klein R., Epelbaum J., Le Bouc Y., Holzenberger M. Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol. 2008, 6:e254.
128. Kido Y., Nakae J., Accili D. Clinical review 125: the insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab. 2001, 86:972-979.
129. Kido Y., Nakae J., Hribal M.L., Xuan S., Efstratiadis A., Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J. Biol. Chem. 2002, 277:36740-36747.
130. Kim J.B., Sarraf P., Wright M., Yao K.M., Mueller E., Solanes G., Lowell B.B., Spiegelman B.M. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest. 1998, 101:1-9.
131. Kim J.K., Michael M.D., Previs S.F., Peroni O.D., Mauvais-Jarvis F., Neschen S., Kahn B.B., Kahn C.R., Shulman G.I. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest. 2000, 105:1791-1797.
132. Kim H.H., DiVall S.A., Deneau R.M., Wolfe A. Insulin regulation of GnRH gene expression through MAP kinase signaling pathways. Mol. Cell Endocrinol. 2005, 242:42-49.
133. Kim B., McLean L.L., Philip S.S., Feldman E.L. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology 2011, 152:3638-3647.
134. Kitamura T., Kahn C.R., Accili D. Insulin receptor knockout mice. Annu. Rev. Physiol. 2003, 65:313-332.
135. Kleinridders A., Ferris H.A., Cai W., Kahn C.R. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014, 63:2232-2243.
136. Kondegowda N.G., Mozar A., Chin C., Otero A., Garcia-Ocana A., Vasavada R.C. Lactogens protect rodent and human beta cells against glucolipotoxicity-induced cell death through Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) signalling. Diabetologia 2012, 55:1721-1732.
137. Kozka I.J., Clark A.E., Holman G.D. Chronic treatment with insulin selectively down-regulates cell-surface GLUT4 glucose transporters in 3T3-L1 adipocytes. J. Biol. Chem. 1991, 266:11726-11731.
138. Kreisberg R.A. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann. Intern Med. 1978, 88:681-695.
139. Kubota T., Kubota N., Kumagai H., Yamaguchi S., Kozono H., Takahashi T., Inoue M., Itoh S., Takamoto I., Sasako T., Kumagai K., Kawai T., Hashimoto S., Kobayashi T., Sato M., Tokuyama K., Nishimura S., Tsunoda M., Ide T., Murakami K., Yamazaki T., Ezaki O., Kawamura K., Masuda H., Moroi M., Sugi K., Oike Y., Shimokawa H., Yanagihara N., Tsutsui M., Terauchi Y., Tobe K., Nagai R., Kamata K., Inoue K., Kodama T., Ueki K., Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011, 13:294-307.
140. Kubota T., Kubota N., Kadowaki T. The role of endothelial insulin signaling in the regulation of glucose metabolism. Rev. Endocr. Metab. Disord. 2013, 14:207-216.
141. Kujiraoka T., Satoh Y., Ayaori M., Shiraishi Y., Arai-Nakaya Y., Hakuno D., Yada H., Kuwada N., Endo S., Isoda K., Adachi T. Hepatic extracellular signal-regulated kinase 2 suppresses endoplasmic reticulum stress and protects from oxidative stress and endothelial dysfunction. J. Am. Heart Assoc. 2013, 2:e000361.
142. Kulkarni R.N. New insights into the roles of insulin/IGF-I in the development and maintenance of beta-cell mass. Rev. Endocr. Metab. Disord. 2005, 6:199-210.
143. Kulkarni R.N., Bruning J.C., Winnay J.N., Postic C., Magnuson M.A., Kahn C.R. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999, 96:329-339.
144. Kulkarni R.N., Holzenberger M., Shih D.Q., Ozcan U., Stoffel M., Magnuson M.A., Kahn C.R. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat. Genet. 2002, 31:111-115.
145. Kulkarni R.N., Mizrachi E.B., Ocana A.G., Stewart A.F. Human beta-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes 2012, 61:2205-2213.
146. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Jonassen I., Schmid C., Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
147. Lammers R., Gray A., Schlessinger J., Ullrich A. Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J. 1989, 8:1369-1375.
148. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell. 2012, 149:274-293.
149. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., Park E., Gee J.M., Finlay P., Jones H.E., Nicholson R.I., Carboni J., Gottardis M., Pollak M., Dunn S.E. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008, 68:10238-10246.
150. Lawrence M.C., McGlynn K., Park B.H., Cobb M.H. ERK1/2-dependent activation of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter. J. Biol. Chem. 2005, 280:26751-26759.
151. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., Pessin J.E., Cuatrecasas P., Saltiel A.R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J. Biol. Chem. 1995, 270:20801-20807.
152. Lee Y.S., Jun H.S. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014, 63:9-19.
153. Leibiger B., Leibiger I.B., Moede T., Kemper S., Kulkarni R.N., Kahn C.R., de Vargas L.M., Berggren P.O. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol. Cell 2001, 7:559-570.
154. Lewitt M.S., Baxter R.C. Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?. Mol. Cell Endocrinol. 1991, 79:C147-C152.
155. Li S., Brown M.S., Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3441-3446.
156. Liu S., Okada T., Assmann A., Soto J., Liew C.W., Bugger H., Shirihai O.S., Abel E.D., Kulkarni R.N. Insulin signaling regulates mitochondrial function in pancreatic beta-cells. PLoS One 2009, 4:e7983.
157. Livingstone C. IGF2 and cancer. Endocr. Relat. Cancer 2013, 20:R321-R339.
158. Lundgren H., Bengtsson C., Blohme G., Lapidus L., Waldenstrom J. Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabet. Med. 1990, 7:407-413.
159. Maddux B.A., Chan A., De Filippis E.A., Mandarino L.J., Goldfine I.D. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 2006, 29:1535-1537.
160. Madsbad S. LY2605541-a preferential hepato-specific insulin analogue. Diabetes 2014, 63:390-392.
161. Marette A., Burdett E., Douen A., Vranic M., Klip A. Insulin induces the translocation of GLUT4 from a unique intracellular organelle to transverse tubules in rat skeletal muscle. Diabetes 1992, 41:1562-1569.
162. Marshall S., Olefsky J.M. Effects of insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes. Evidence for hormone-induced desensitization at the receptor and postreceptor level. J. Clin. Invest. 1980, 66:763-772.
163. Mather K., Laakso M., Edelman S., Hook G., Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E1264-E1270.
164. Mauvais-Jarvis F., Virkamaki A., Michael M.D., Winnay J.N., Zisman A., Kulkarni R.N., Kahn C.R. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes 2000, 49:2126-2134.
165. Mayer C.M., Belsham D.D. Insulin directly regulates NPY and AgRP gene expression via the MAPK MEK/ERK signal transduction pathway in mHypoE-46 hypothalamic neurons. Mol. Cell Endocrinol. 2009, 307:99-108.
166. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992, 258:766-770.
167. McGarry J.D., Foster D.W. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. Biochem. 1980, 49:395-420.
168. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121.
169. McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., Fernley R.T., Epa V.C., Ward C.W. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006, 443:218-221.
170. Melien O., Nilssen L.S., Dajani O.F., Sand K.L., Iversen J.G., Sandnes D.L., Christoffersen T. Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases. BMC Cell Biol. 2002, 3:5.
171. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., Kahn C.R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 2000, 6:87-97.
172. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
173. Miinea C.P., Sano H., Kane S., Sano E., Fukuda M., Peranen J., Lane W.S., Lienhard G.E. AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. Biochem. J. 2005, 391:87-93.
174. Milazzo G., Giorgino F., Damante G., Sung C., Stampfer M.R., Vigneri R., Goldfine I.D., Belfiore A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992, 52:3924-3930.
175. Mistry T., Digby J.E., Desai K.M., Randeva H.S. Obesity and prostate cancer: a role for adipokines. Eur. Urol. 2007, 52:46-53.
176. Mohammed F.F., Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol. 2005, 15:555-563.
177. Molina J., Rodriguez-Diaz R., Fachado A., Jacques-Silva M.C., Berggren P.O., Caicedo A. Control of insulin secretion by cholinergic signaling in the human pancreatic islet. Diabetes 2014, 63:2714-2726.
178. Moller D.E., Yokota A., Caro J.F., Flier J.S. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol. 1989, 3:1263-1269.
179. Montagnani M., Golovchenko I., Kim I., Koh G.Y., Goalstone M.L., Mundhekar A.N., Johansen M., Kucik D.F., Quon M.J., Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem. 2002, 277:1794-1799.
180. Moon H.S., Chamberland J.P., Mantzoros C.S. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C(2)C(1)(2) muscle and AML12 liver cell lines. Diabetologia 2012, 55:215-225.
181. Moore M.C., Smith M.S., Sinha V.P., Beals J.M., Michael M.D., Jacober S.J., Cherrington A.D. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014, 63:494-504.
182. Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990, 9:2409-2413.
183. Muniyappa R., Iantorno M., Quon M.J. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol. Metab. Clin. North Am. 2008, 37:685-711. ix-x.
184. Nadal A., Marrero P.F., Haro D. Down-regulation of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by insulin: the role of the forkhead transcription factor FKHRL1. Biochem. J. 2002, 366:289-297.
185. Nakae J., Kido Y., Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 2001, 22:818-835.
186. Nakae J., Biggs W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 2002, 32:245-253.
187. Nandi A., Kitamura Y., Kahn C.R., Accili D. Mouse models of insulin resistance. Physiol. Rev. 2004, 84:623-647.
188. Niu X.L., Li J., Hakim Z.S., Rojas M., Runge M.S., Madamanchi N.R. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J. Biol. Chem. 2007, 282:19808-19819.
189. Nouspikel T., Iynedjian P.B. Insulin signalling and regulation of glucokinase gene expression in cultured hepatocytes. Eur. J. Biochem. 1992, 210:365-373.
190. O'Malley D., Harvey J. MAPK-dependent actin cytoskeletal reorganization underlies BK channel activation by insulin. Eur. J. Neurosci. 2007, 25:673-682.
191. Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 2002, 8:1376-1382.
192. Obici S., Feng Z., Karkanias G., Baskin D.G., Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat. Neurosci. 2002, 5:566-572.
193. Oh K.J., Han H.S., Kim M.J., Koo S.H. Transcriptional regulators of hepatic gluconeogenesis. Arch. Pharm. Res. 2013, 36:189-200.
194. Okada T., Liew C.W., Hu J., Hinault C., Michael M.D., Krtzfeldt J., Yin C., Holzenberger M., Stoffel M., Kulkarni R.N. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8977-8982.
195. Okamoto H., Nakae J., Kitamura T., Park B.C., Dragatsis I., Accili D. Transgenic rescue of insulin receptor-deficient mice. J. Clin. Invest. 2004, 114:214-223.
196. Otani K., Kulkarni R.N., Baldwin A.C., Krutzfeldt J., Ueki K., Stoffel M., Kahn C.R., Polonsky K.S. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E41-E49.
197. Otero Y.F., Stafford J.M., McGuinness O.P. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J. Biol. Chem. 2014, 289:20462-20469.
198. Pages G., Guerin S., Grall D., Bonino F., Smith A., Anjuere F., Auberger P., Pouyssegur J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286:1374-1377.
199. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 2002, 277:39684-39695.
200. Park K., Li Q., Rask-Madsen C., Mima A., Mizutani K., Winnay J., Maeda Y., D'Aquino K., White M.F., Feener E.P., King G.L. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol. Cell Biol. 2013, 33:3227-3241.
201. Peak M., Rochford J.J., Borthwick A.C., Yeaman S.J., Agius L. Signalling pathways involved in the stimulation of glycogen synthesis by insulin in rat hepatocytes. Diabetologia 1998, 41:16-25.
202. Pende M., Kozma S.C., Jaquet M., Oorschot V., Burcelin R., Le Marchand-Brustel Y., Klumperman J., Thorens B., Thomas G. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000, 408:994-997.
203. Plomgaard P., Bouzakri K., Krogh-Madsen R., Mittendorfer B., Zierath J.R., Pedersen B.K. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54:2939-2945.
204. Pocai A., Lam T.K., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005, 434:1026-1031.
205. Prusty D., Park B.H., Davis K.E., Farmer S.R. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J. Biol. Chem. 2002, 277:46226-46232.
206. Rajagopal S., Ahn S., Rominger D.H., Gowen-MacDonald W., Lam C.M., Dewire S.M., Violin J.D., Lefkowitz R.J. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 2011, 80:367-377.
207. Ramalingam L., Oh E., Thurmond D.C. Novel roles for insulin receptor (IR) in adipocytes and skeletal muscle cells via new and unexpected substrates. Cell Mol. Life Sci. 2013, 70:2815-2834.
208. Rask-Madsen C., Kahn C.R. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2052-2059.
209. Reusch J.E., Bhuripanyo P., Carel K., Leitner J.W., Hsieh P., DePaolo D., Draznin B. Differential requirement for p21ras activation in the metabolic signaling by insulin. J. Biol. Chem. 1995, 270:2036-2040.
210. Ricort J.M., Tanti J.F., Van Obberghen E., Le Marchand-Brustel Y. Alterations in insulin signalling pathway induced by prolonged insulin treatment of 3T3-L1 adipocytes. Diabetologia 1995, 38:1148-1156.
211. Rizza R.A., Mandarino L.J., Gerich J.E. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am. J. Physiol. 1981, 240:E630-E639.
212. Rizza R.A., Mandarino L.J., Genest J., Baker B.A., Gerich J.E. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985, 28:70-75.
213. Rojdmark S., Bloom G., Chou M.C., Jaspan J.B., Field J.B. Hepatic insulin and glucagon extraction after their augmented secretion in dogs. Am. J. Physiol. 1978, 235:E88-E96.
214. Rose D.P., Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr. Relat. Cancer 2012, 19:R225-R241.
215. Rosen E.D., MacDougald O.A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006, 7:885-896.
216. Rosen E.D., Walkey C.J., Puigserver P., Spiegelman B.M. Transcriptional regulation of adipogenesis. Genes Dev. 2000, 14:1293-1307.
217. Ruiz-Alcaraz A.J., Lipina C., Petrie J.R., Murphy M.J., Morris A.D., Sutherland C., Cuthbertson D.J. Obesity-induced insulin resistance in human skeletal muscle is characterised by defective activation of p42/p44 MAP kinase. PLoS One 2013, 8:e56928.
218. Ryder J.W., Chibalin A.V., Zierath J.R. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol. Scand. 2001, 171:249-257.
219. Sajan M.P., Standaert M.L., Bandyopadhyay G., Quon M.J., Burke T.R., Farese R.V. Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes. J. Biol. Chem. 1999, 274:30495-30500.
220. Sajan M.P., Jurzak M.J., Samuels V.T., Shulman G.I., Braun U., Leitges M., Farese R.V. Impairment of insulin-stimulated glucose transport and ERK activation by adipocyte-specific knockout of PKC-lambda produces a phenotype characterized by diminished adiposity and enhanced insulin suppression of hepatic gluconeogenesis. Adipocyte 2014, 3:19-29.
221. Sakamoto K., Goodyear L.J. Invited review: intracellular signaling in contracting skeletal muscle. J. Appl. Physiol. (1985) 2002, 93:369-383.
222. Sakamoto K., Aschenbach W.G., Hirshman M.F., Goodyear L.J. Akt signaling in skeletal muscle: regulation by exercise and passive stretch. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E1081-E1088.
223. Sakamoto K., McCarthy A., Smith D., Green K.A., Grahame Hardie D., Ashworth A., Alessi D.R. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 2005, 24:1810-1820.
224. Saladin R., De Vos P., Guerre-Millo M., Leturque A., Girard J., Staels B., Auwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995, 377:527-529.
225. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
226. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiol. (Bethesda) 2008, 23:160-170.
227. Schaeffer M., Hodson D.J., Mollard P. The blood-brain barrier as a regulator of the gut-brain axis. Front. Horm. Res. 2014, 42:29-49.
228. Sciacca L., Mineo R., Pandini G., Murabito A., Vigneri R., Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002, 21:8240-8250.
229. Sciacca L., Cassarino M.F., Genua M., Pandini G., Le Moli R., Squatrito S., Vigneri R. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010, 53:1743-1753.
230. Sciacca L., Le Moli R., Vigneri R. Insulin analogs and cancer. Front. Endocrinol. (Lausanne) 2012, 3:21.
231. Seino S., Bell G.I. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Commun. 1989, 159:312-316.
232. Serrano R., Villar M., Martinez C., Carrascosa J.M., Gallardo N., Andres A. Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. J. Mol. Endocrinol. 2005, 34:153-161.
233. Sesti G., Tullio A.N., D'Alfonso R., Napolitano M.L., Marini M.A., Borboni P., Longhi R., Albonici L., Fusco A., Agliano A.M., et al. Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetol. 1994, 31:59-65.
234. Sharon R., Pillemer G., Ish-Shalom D., Kalman R., Ziv E., Berry E.M., Naor D. Insulin dependence of murine T-cell lymphoma. II. Insulin-deficient diabetic mice and mice fed low-energy diet develop resistance to lymphoma growth. Int. J. Cancer 1993, 53:843-849.
235. Shepherd P.R., Withers D.J., Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 1998, 333(Pt 3):471-490.
236. Shiflett M.W., Balleine B.W. Contributions of ERK signaling in the striatum to instrumental learning and performance. Behav. Brain Res. 2011, 218:240-247.
237. Shoba L.N., Newman M., Liu W., Lowe W.L. LY 294002, an inhibitor of phosphatidylinositol 3-kinase, inhibits GH-mediated expression of the IGF-I gene in rat hepatocytes. Endocrinology 2001, 142:3980-3986.
238. Shojaee-Moradie F., Powrie J.K., Sundermann E., Spring M.W., Schuttler A., Sonksen P.H., Brandenburg D., Jones R.H. Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 2000, 23:1124-1129.
239. Siddle K., Urso B., Niesler C.A., Cope D.L., Molina L., Surinya K.H., Soos M.A. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem. Soc. Trans. 2001, 29:513-525.
240. Sjogren K., Liu J.L., Blad K., Skrtic S., Vidal O., Wallenius V., LeRoith D., Tornell J., Isaksson O.G., Jansson J.O., Ohlsson C. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7088-7092.
241. Souza Pauli L.S., Ropelle E.C., de Souza C.T., Cintra D.E., da Silva A.S., de Almeida Rodrigues B., de Moura L.P., Marinho R., de Oliveira V., Katashima C.K., Pauli J.R., Ropelle E.R. Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice. J. Physiol. 2014, 592:1325-1340.
242. Steelman L.S., Chappell W.H., Abrams S.L., Kempf R.C., Long J., Laidler P., Mijatovic S., Maksimovic-Ivanic D., Stivala F., Mazzarino M.C., Donia M., Fagone P., Malaponte G., Nicoletti F., Libra M., Milella M., Tafuri A., Bonati A., Basecke J., Cocco L., Evangelisti C., Martelli A.M., Montalto G., Cervello M., McCubrey J.A. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011, 3:192-222.
243. Stein D.T., Esser V., Stevenson B.E., Lane K.E., Whiteside J.H., Daniels M.B., Chen S., McGarry J.D. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 1996, 97:2728-2735.
244. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 2004, 14:395-403.
245. Tan S.X., Ng Y., Meoli C.C., Kumar A., Khoo P.S., Fazakerley D.J., Junutula J.R., Vali S., James D.E., Stockli J. Amplification and demultiplexing in insulin-regulated Akt protein kinase pathway in adipocytes. J. Biol. Chem. 2012, 287:6128-6138.
246. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
247. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
248. Thorn S.R., Sekar S.M., Lavezzi J.R., O'Meara M.C., Brown L.D., Hay W.W., Rozance P.J. A physiological increase in insulin suppresses gluconeogenic gene activation in fetal sheep with sustained hypoglycemia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303:R861-R869.
249. Tompkins C.V., Brandenburg D., Jones R.H., Sonksen P.H. Mechanism of action of insulin and insulin analogues. A comparison of the hepatic and peripheral effects on glucose turnover of insulin, proinsulin and three insulin analogues modified at positions A1 and B29. Diabetologia 1981, 20:94-101.
250. Tsuchiya K., Tanaka J., Shuiqing Y., Welch C.L., DePinho R.A., Tabas I., Tall A.R., Goldberg I.J., Accili D. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 2012, 15:372-381.
251. Unger R.H., Cherrington A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 2012, 122:4-12.
252. Vasavada R.C., Wang L., Fujinaka Y., Takane K.K., Rosa T.C., Mellado-Gil J.M., Friedman P.A., Garcia-Ocana A. Protein kinase C-zeta activation markedly enhances beta-cell proliferation: an essential role in growth factor mediated beta-cell mitogenesis. Diabetes 2007, 56:2732-2743.
253. Vicent D., Ilany J., Kondo T., Naruse K., Fisher S.J., Kisanuki Y.Y., Bursell S., Yanagisawa M., King G.L., Kahn C.R. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 2003, 111:1373-1380.
254. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R. Diabetes and cancer. Endocr. Relat. Cancer 2009, 16:1103-1123.
255. Vigneri R., Squatrito S., Frittitta L. Selective insulin receptor modulators (SIRM): a new class of antidiabetes drugs?. Diabetes 2012, 61:984-985.
256. Vincent M.A., Barrett E.J., Lindner J.R., Clark M.G., Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E123-E129.
257. Vincent M.A., Clerk L.H., Lindner J.R., Klibanov A.L., Clark M.G., Rattigan S., Barrett E.J. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004, 53:1418-1423.
258. von der Thusen J.H., Borensztajn K.S., Moimas S., van Heiningen S., Teeling P., van Berkel T.J., Biessen E.A. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am. J. Pathol. 2011, 178:924-934.
259. Waldbillig R.J., LeRoith D. Insulin receptors in the peripheral nervous system: a structural and functional analysis. Brain Res. 1987, 409:215-220.
260. Wang C.C., Goalstone M.L., Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53:2735-2740.
261. Wang C.F., Zhang G., Zhao L.J., Qi W.J., Li X.P., Wang J.L., Wei L.H. Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth. PLoS One 2013, 8:e69001.
262. Wang H., Qin J., Gong S., Feng B., Zhang Y., Tao J. Insulin-like growth factor-1 receptor-mediated inhibition of A-type K(+) current induces sensory neuronal hyperexcitability through the phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 pathways, independently of Akt. Endocrinology 2014, 155:168-179.
263. Weng L.P., Smith W.M., Brown J.L., Eng C. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum. Mol. Genet. 2001, 10:605-616.
264. Wiegert J.S., Bading H. Activity-dependent calcium signaling and ERK-MAP kinases in neurons: a link to structural plasticity of the nucleus and gene transcription regulation. Cell Calcium 2011, 49:296-305.
265. Wiese R.J., Mastick C.C., Lazar D.F., Saltiel A.R. Activation of mitogen-activated protein kinase and phosphatidylinositol 3'-kinase is not sufficient for the hormonal stimulation of glucose uptake, lipogenesis, or glycogen synthesis in 3T3-L1 adipocytes. J. Biol. Chem. 1995, 270:3442-3446.
266. Wojtaszewski J.F., Higaki Y., Hirshman M.F., Michael M.D., Dufresne S.D., Kahn C.R., Goodyear L.J. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J. Clin. Invest. 1999, 104:1257-1264.
267. Wojtaszewski J.F., Lynge J., Jakobsen A.B., Goodyear L.J., Richter E.A. Differential regulation of MAP kinase by contraction and insulin in skeletal muscle: metabolic implications. Am. J. Physiol. 1999, 277:E724-E732.
268. Wu X., Williams K.J. NOX4 pathway as a source of selective insulin resistance and responsiveness. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1236-1245.
269. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002, 62:1030-1035.
270. Wu Y., Cui K., Miyoshi K., Hennighausen L., Green J.E., Setser J., LeRoith D., Yakar S. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003, 63:4384-4388.
271. Yakar S., Liu J.L., Fernandez A.M., Wu Y., Schally A.V., Frystyk J., Chernausek S.D., Mejia W., Le Roith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50:1110-1118.
272. Yang X., Wei A., Liu Y., He G., Zhou Z., Yu Z. IGF-1 protects retinal ganglion cells from hypoxia-induced apoptosis by activating the Erk-1/2 and Akt pathways. Mol. Vis. 2013, 19:1901-1912.
273. Zheng Y., Zhang W., Pendleton E., Leng S., Wu J., Chen R., Sun X.J. Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J. Endocrinol. 2009, 203:337-347.
274. Zhu B., Zhao G., Witte D.P., Hui D.Y., Fagin J.A. Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology 2001, 142:3598-3606.